Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors

Journal of Cellular Biochemistry

Volumn 68, Issue 2, 1998, Pages 186-194

  Klein, Benjamin Y ^a,c   Ben Bassat, Hannah ^a   Breuer, Eli ^b   Solomon, Vered ^b   Golomb, Gershon ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Alkaline phosphatase; Bisphosphonates; Cell proliferation; Marrow stroma; Mineralization; Osteoprogenitors

Indexed keywords

2 (3' DIMETHYLAMINOPYRAZINIO)ETHYLIDENE 1,1 BISPHOSPHONIC ACID BETAINE; ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE MINERALIZATION; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RAT; STEM CELL; STROMA CELL;

ALENDRONATE; ALKALINE PHOSPHATASE; ANIMALS; BETAINE; BONE MARROW CELLS; CALCIFICATION, PHYSIOLOGIC; CELL DIVISION; CELLS, CULTURED; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYDROLYSIS; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; OSTEOBLASTS; RATS; RATS, INBRED STRAINS; STEM CELLS; STROMAL CELLS; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 0031974325     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(19980201)68:2<186::AID-JCB5>3.0.CO;2-R     Document Type: Article

References (50)

1. Anagnostou F, Plas C, Forest N (1996): Ecto-alkaline phosphatase considered as levamisole-sensitive phosphohydrolase at physiological pH range during mineralization in cultured fetal calvaria cells. J Cell Biochem 60:484-494.
2. Averbuch SD (1993): New bisphosphonates in the treatment of bone metastases. Cancer 72:3443-3452.
3. Bellows CG, Aubin JE, Heersche JNM (1987): Physiological concentrations of glucocorticoids stimulate formation of bone nodules from isolated rat calvaria cells in vitro. Endocrinology 121:1985-1992.
4. Bijvoet OLM, Valkema R, Lowik CWGM, Papapoulos SE (1993): Bisphosphonates in Osteoporosis? Osteoporosis Int 1:S230-S236.
5. Blomqvist C, Elomaa I (1996): Bisphosphonate therapy in metastatic breast cancer. Acta Oncol 35(Suppl):81-83.
6. Body JJ, Coleman RE, Piccart M (1996): Use of bisphosphonates in cancer patients. Cancer Treat Rev 22:265-287.
7. Chappelet-Tordo D, Fosset M, Iwatsubo M, Gache C, Lazdunski M (1974): Intestinal alkaline phosphatase. Catalytic properties and half of the site reactivity. Biochemistry 13:1788-1795.
8. Cleland WW (1977): Determining the chemical mechanisms of enzyme catalysed reactions by kinetic studies. Adv Enzymol 45:273-357.
9. Cohen H, Breuer E, Chen R, Solomon V, Ornoy A, Patlas N, Pinto T, Golomb G (1996): Synthesis and evaluation of nitrogen-containing novel bisphosphonates for calcium-related disorders. Pharm Res 13:s-139.
10. Cyboron GW, Vejins MS, Wuthier RE (1982): Activity of epiphyseal cartilage membrane alkaline phosphatase and the effect of its inhibitor on at physiological pH. J Biol Chem 257:4141-4146.
11. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996): Esophagitis associated with the use of alendronate. New Engl J Med 335:1016-1021.
12. Delmas PD, Meunier PJ (1997): The management of Paget's disease of bone. New Engl J Med 336:558-566.
13. Fallon MD, Whyte MP, Teitelbaum SL (1980): Stereospecific inhibition of alkaline phosphatase by L-Tetramisole prevents in vitro cartilage calcification. Lab Invest 43: 489-494.
14. Felix R, Fleisch H (1979): Increase in alkaline phosphatase activity in calvarial cells cultured with disphosphonates. Biochem J 183:73-81.
15. 14C 1-hydroxyethyleden-l, 1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int 36:108-113.
16. Flanagan AM, Chambers TJ (1991): Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49:407-415.
17. Fleisch H (1989): Bisphosphonates: A new class of drugs in diseases of bone and calcium metabolism. In Brunner KW, Fleisch H, Senn H-J (eds): "Bisphosphonates and Tumor Osteolysis." Berlin Heidelberg: Springer-Verlag, pp 1-29.
18. Fleisch H (1993): Bisphosphonates: Mechanism of action and clinical use. In Mundy GR, Martin TJ (eds): "Physiology and Pharmacology of Bone." Heidelberg: Springer-Verlag.
19. Fleisch HA (1997): Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 29:55-62.
20. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ (1994): Bisphosphonates: Structure-activity relationships and therapeutic implications. In Heersche JNM, Kanis JA (eds): "Bone and Mineral Research." Amsterdam: Elsevier, pp 265-306.
21. Kamalia N, McCulloch CAG, Tenenbaum HC, Limback H (1992): Dexamethasone recruitment of self-renewing osteoprogenitor cells in chick bone marrow stromal cell culture. Blood 79:320-326.
22. Klein BY, Gal I, Segal D (1993a): Selection of malonate-resistant stromal cell-derived osteoprogenitor cells in vitro. J Cell Biochem 51:190-197.
23. Klein BY, Gal I, Segal D (1993b): Studies of the levamisole inhibitory effect on rat stromal-cell commitment to mineralization. J Cell Biochem 53:114-121.
24. Klein BY, Rojansky N, Gal I, Shlomai Z, Liebergall M, Ben-Bassat H (1995): Analysis of cell-mediated mineralization in culture of bone derived embryonic cells with neurofibromatosis. J Cell Biochem 57:530-542.
25. Klein BY, Gal I, Libergall M, Ben-Bassat H (1996): Opposing effects on mitochondrial membrane potential by malonate and levamisole, whose effect on cell-mediated mineralization is antagonistic. J Cell Biochem 60:139-147.
26. Leboy PS, Beresford JN, Devin C, Owen ME (1991): Dexamethasone induction of osteoblast mRNAs in rat marrow stromal cell cultures. J Cell Physiol 146:370-378.
27. Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora II AC, Lombardi A, Shan RV, Hirsch LJ, Karpf DB (1995): Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New Engl J Med 333:1437-1443.
28. Maniatopoulos C, Sodek J, Melcher AH (1988): Bone formation in vitro by stromal cells obtained from bone marrow of young adult rats. Cell Tissue Res 254:317-330.
29. Muhlbauer RC (1995): Mechanisms of action of bisphosphonates: Information from animal models. In OLM Bijvoet, HA Fleisch, RE Canfield, RGG Russell (eds): "Bisphosphonates on Bones." Amsterdam: Elsevier Science B.V., pp 171-187.
30. Nijweide PJ, Kawilarang-de Has EWM, Wassenaar AM (1981): Alkaline phosphatase and calcification correlated or not? Metab Bone Dis Related Res 3:61-66.
31. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugai N, Yamamoto M, Nagata N (1996): Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9-14.
32. Pockwinze SM, Wiming LG, Conlon DM, Stein GS, Lian JB (1992): Expression of cell growth and bone specific genes at single cell resolution during development of bone tissue-like organization in primary osteoblast cultures. J Cell Biochem 49:310-323.
33. Raisz LG (1997): The osteoporosis revolution. Ann Intern Med 126:458-462.
34. Rodan GA, Balena R (1993): Bisphosphonates in the treatment of metabolic bone diseases. Ann Med 25:373-378.
35. Rosen SW, Klotz IM (1957): Phosphans analogues as inhibitors of the beef heart succinic dehydrogenase system. Arch Biochem Biophys 67:161-168.
36. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ (1993): Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91: 2004-2011.
37. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA (1991): Bisphosphonate action. J Clin Invest 88:2095-2105.
38. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA (1996): Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate. Proc Natl Acad Sci USA 93: 3068-3073.
39. Segel IH (1976): Enzymes as biological catalysts. In Irwin H, Segel J (eds): "Biochemical Calculations." New York: Wiley & Sons, pp 208-319.
40. Shapiro IM, Lee NH (1978): The effect of oxygen, phosphoenolpyruvate, and pH on the release of calcium from chondrocyte mitochondria. Metab Bone Dis Relate Res 1:173-177.
41. Shinozaki T, Pritzker KP (1996): Regulation of alkaline-phosphatase, implications for calcium pyrophosphate dehydrate crystal dissolution and other alkaline phosphatase functions. J Rheumatol 23:677-683.
42. Siris ES (1997): Breast cancer and osteolytic metastases: Can bisphosphonates help. Nature Med 3:151-152.
43. Stein GS, Lian JB, Owen TA (1990): Relationship of cell growth to the regulation of tissue specific gene expression during osteoblast differentiation. FASEB J 4:3111-3123.
44. Sunberg SJ, Ebetino FH, Mosher CT, Root CF (1991): Designing drugs for stronger bones. Chemtech 21:304-309.
45. Tenenbaum HC, Torontali M, Sukhu B (1992): Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 13:249-255.
46. Twiss IM, de Water R, den Hartigh J, Sparidans R, Ramp-Koopmanschap W, Brill H, Wijdeveld M, Vermeij P (1994): Cytotoxic effects of Pamodronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci 83:699-703.
47. Van Beek E, Hoekstra M, Van de Ruit M, Lowik CWGM, Papapoulos SE (1994): Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9:1875-1882.
48. Van Gelder JM, Golomb G (1995): The evaluation of bisphosphonates as potential drugs for the treatment of calcium-related disorders. In Ornoy A (ed): "Animal Models of Human Related Calcium Metabolic Disorders." Boca Raton, FL: CRC Press, pp 181-205.
49. Van Gelder JM, Breuer E, Ornoy A, Schlossman A, Patlas N, Golomb G (1995): Anticalcification and antiresorption effects of bisacylphosphonates. Bone 16:511-520.
50. Vitte C, Fleisch H, Guenther HL (1996): Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324-2333.